Fulcrum Therapeutics, Inc. (FULC) has a consensus analyst rating of Buy, based on 16 analysts covering the stock. Of those, 11 recommend buying, 4 recommend holding, and 1 recommend selling.
The analyst consensus price target for FULC is $20.57, representing a +160.4% upside from the current price of $7.9. Price targets range from a low of $10.00 to a high of $25.00.
